Phase 3 Gastroparesis Trial, Recruiting NCT06836557 Sponsor: Vanda Pharmaceuticals Condition: Gastroparesis
Back to Gastroparesis

Phase 3 Gastroparesis Trial, Recruiting

NCT06836557
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with gastroparesis (a condition where the stomach empties food more slowly than normal)
  • Tests have confirmed that your stomach empties more slowly than it should
  • You experience moderate to severe nausea
  • Your Body Mass Index (BMI) is between 18 and 40 (a measure of body weight relative to height)

Who may not be able to join:

  • You have another condition or are receiving a treatment that could be causing or adding to your stomach symptoms
  • A drug screening test at your initial appointments shows the presence of non-prescribed or recreational drugs
  • You are currently pregnant or breastfeeding
  • Your blood sugar levels are not well controlled, including having a specific blood sugar marker (HbA1c) above 11% at your first appointment, or having had a serious blood sugar-related health crisis in the past 60 days

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Vanda Pharmaceuticals, Vanda Pharmaceuticals

Phone: 202-734-3400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Vanda Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
9 January 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇧🇪 Belgium 🇩🇪 Germany

Primary endpoints

Number of participants with adverse events (AEs), including suicidal ideation or behavior as measured by the C-SSRS; Number of participants with changes in vital signs identified as Clinically Notable Abnormal values; Number of participants with abnormal and potentially Clinically Notable Abnormal Electrocardiogram Intervals and Heart Rate; Number of participants with Clinically Notable Abnormal laboratory values

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov